Skip to main content

Tuesday, May 30th, 2017 -- Buyout soon?

Will the buy out happen before the end of P3?


I think it will, and there's a precedent for this.   Read about the Biogen purchase of a late stage biotech.   Biogen experience Also, Ariad was purchased because of Brigatinib, which was not approved until five months after the buyout.

What are your thoughts?

Thanks everyone!

TC

Comments

  1. I would be surprised if the company is NOT acquired before the end of phase 3. With compelling phase 2 data and a good possibility of replacing Restasis as the best drug for dry eye syndrome, why would a BP wait to pay more for AUPH when it could pay much less before the LN indication is approved? That makes little sense. In addition, you can bet that Mr. Duggan will be advocating for a fast return on his huge investment and advising Glickman just exactly how to get it done. My bet is we see a buyout within 12-18 months if not sooner. Every month that goes by raises the price on the company. I am hoping that the mms take this down to the 5's this week at which point I am a buyer again.

    ReplyDelete
    Replies
    1. Yep, I agree. Amazing downward pressure, and no doubt many retailers will cave and accept a loss. This stock, and these biotech games, are not for the faint of heart. It's hard to forget the facts at times like these, and therefore good to recall them....Phase 2b results were superb, and lead to estimates of the company being worth 3+ billion. Phase 3 is just getting underway, so there's no "bad news" to explain the downward price movement - the value of this company has not changed one bit, and it actually increases over time as we get closer to the BO and results from P3. Time to turn of the computer, I believe.

      Delete
    2. In the absence of news the mms are free to play the sp as much as they want. Panicky retailers inevitably sell at the worst time. Institutional investors are buying the cheap shares as they become available and the percentage of institutional investment continues to rise. At some point an equilibrium will be reached and than the sp may remain at that level for quite awhile. Many retailers already worn down will eventually have had enough and sell at that level. When things look hopeless the few remaining retailers and the patient institutional investors will watch as the sp alowly starts to ascend culminating in a buyout. This process will occur within 2 years imo. Will be watching to see how low they can take it before it reaches equilibrium. My guess is low 5s or high 4s. Might put in a bid at that level.

      Delete
    3. "My guess is low 5s or high 4s. " If that happens, what an incredible gift!

      “The best thing that happens to us is when a great company gets into temporary trouble... We want to buy them when they're on the operating table.”
      -Buffet 1999.

      “And if they insist on trying to time their participation in equities, they should try to be fearful when others are greedy and greedy only when others are fearful.” -Buffet 2004

      cheers



      Delete

Post a Comment

Popular posts from this blog

June 6, 2017. Buy Out at 63?

Take a spin on our BO pricing model! The Trading Cyclist Our model is generating a range of $35-63 BO PPS , per the low/high case scenarios below - where only the Voc  price  is different (25 k vs 50k). My hunch is that this is both conservative and in the ballpark.  It's conservative b/c: 1) patient population is consistent with Aurinia's projection; 2) assumes only 35% of population on treatment; 3) assumes 75% discount for European market; 4) pricing is at 50% of range projected by Aurinia; 5) uses target P/S ratio of 3, which is below Biotech industry average of 5.0.  Outcome   Patient Pool  (Same for both Scenarios)  Pricing :  Price/Sales ratio   Here's the  Link to the model Low end BO PPS w/30% discount:  $35  ($50 no discount)  High End BO PPS w/30% discount  $63  ($90 no discount)  Prev: 26.5 per 100,000 (Based on epidemiological study)  Total Patient pool (US, Europe, Japan): 252,333  % of patients on treatment: 50%  To

June 8, 2017: The case for early approval of Voclosporin

Voclosporin will likely be approved well before the P3 trial runs it course. Here's how it's going to work.  First, there's a legal and regulatory path for this approval .  While I quote the relevant passage below, here's the link to the  FDA Regulations , as well as  a   list of drugs   t hat received accelerated approval.  Sec. 314.510 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity. FDA may grant marketing approval for a new drug product on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoin t that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. Approval under this section will be subject to the requirement that the applicant stud

iHub has been hijacked by trolls

Yup. iHub can't get rid of "Biotech Researcher," aka BR.  It's both a win for BR (the troll), and a huge loss for iHub. Their platform loses value and credibility when they refuse to take action on perma-trolls that derail the discussion and distract investors from their efforts to just honestly share information and opinions on the equities they own. So shame on iHub for not taking action to resolve this. I'm going to cease and desist on posting there until the troll (BR) problem has been resolved, and credible, valuable posters have been reinstated. I've already cancelled my premium membership some time ago. I suggest you do the same. With kind regards to all Trading Cyclist (aka TC)